Access cutting-edge chronic lymphocytic leukemia treatment through this clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.
Access chronic lymphocytic leukemia specialists in Portland at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic lymphocytic leukemia treatment provided free
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this chronic lymphocytic leukemia clinical trial in Portland, OR
If you're searching for chronic lymphocytic leukemia treatment options in Portland, OR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Portland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic lymphocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.